Spruce Biosciences

Where science meets compassion to deliver targeted therapies for serious neurological disorders.

[Spruce Biosciences @Spruce_Bio]

We are grateful for Dr. Nicole Maria Muschol’s presentation of long-term clinical data on Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in patients with in patients with Sanfilippo Syndrome Type B (MPS IIIB) over the weekend at #MPS2026. https://t.co/jhhWLSTzfe

[Spruce Biosciences @Spruce_Bio]

Next month, data on the long-term administration of TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented in an encore presentation at the International MPS Symposium, taking place June 4–7 in Florence, Italy.
$SPRB

https://t.co/FQoTwopeHD

[Spruce Biosciences @Spruce_Bio]

Next week, our CEO Javier Szwarcberg will present at the Jefferies Global Healthcare Conference in NYC. 
$SPRB

Access the live webcast here: https://t.co/DXm0sZtTY0

[Spruce Biosciences @Spruce_Bio]

We announced our Q1 2026 results today. Visit our
News & Events page for updates on long‑term TA‑ERT
data from WORLDSymposium™ and recent additions to
our leadership team. Full release: https://t.co/ADgMTcCwvj
$SPRB

[Spruce Biosciences @Spruce_Bio]

Tune in to the most recent episode of the Empowered Patient Podcast as CEO @JavierSzwa explores MPS IIIB, why it’s difficult to initially diagnose and the urgent need for an effective treatment for these patients: https://t.co/vJ5D8J8AK5
$SPRB

[Spruce Biosciences @Spruce_Bio]

We’re excited to welcome Brian Walls (VP, Market Access) & Darren Johnson (VP, Commercial Operations) as we continue building toward a potential launch of TA‑ERT for MPS IIIB. $SPRB https://t.co/Wq6yYvtdME

[Spruce Biosciences @Spruce_Bio]

Today, we announced our 2025 financial results and corporate updates. Visit our ‘News & Events’ page to learn more about our latest company highlights, including positive Type B meetings with the FDA for our TA-ERT program. View the press release here:
https://t.co/hBIPKQ3ozt

[Spruce Biosciences @Spruce_Bio]

Today, we welcomed Dale Hooks as our Chief Commercial Officer to lead the potential U.S. commercial launch for our tralesinidase alfa enzyme replacement therapy (TA-ERT). $SPRB https://t.co/OzcWaCWMQ9

[Spruce Biosciences @Spruce_Bio]

Next week, our CEO Javier Szwarcberg, MD, MPH, will participate in two fireside chats at the Leerink Global Healthcare Conference and The Citizens Life Sciences Conference in Miami. https://t.co/DC2ep0qQvr $SPRB

[Spruce Biosciences @Spruce_Bio]

We announced today that we successfully completed Type B meetings with the FDA ahead of our planned upcoming BLA submission for tralesinidase  alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B. https://t.co/iFNiaJ3XeV

[Spruce Biosciences @Spruce_Bio]

Next week, our CEO Javier Szwarcberg, MD, MPH, will participate in a fireside chat Oppenheimer 36th Annual Healthcare Life Sciences Conference. Learn more and access the webcast here: https://t.co/wr7S9uk6AP
$SPRB

[Spruce Biosciences @Spruce_Bio]

Long -Term data presented today at the 22ndAnnual WORLDSymposium™
highlighted Tralesinidase Alfa Enzyme Replacement Therapy’s (TA-ERT) as the first disease-modifying treatment option for Sanfilippo Syndrome Type B (MPS IIIB). https://t.co/v61X0dhjjj $SPRB

[Spruce Biosciences @Spruce_Bio]

We’ve welcomed two new additions to our leadership team to bolster our regulatory and clinical development expertise – Daven Mody, Pharm.D., as SVP of Regulatory & Quality, and Bruno Gagnon, B.Pharm., MSc, as SVP, Clinical Development Operations. https://t.co/6APrrTERWd

[Spruce Biosciences @Spruce_Bio]

Next week, we will present two data presentations of our tralesinidase alfa enzyme replacement therapy (TA-ERT) at the 22nd Annual WORLDSymposium. #WORLDSymposia https://t.co/c6EEHkvjlO
$SPRB

[Spruce Biosciences @Spruce_Bio]

Today, we announced we secured up to $50 million in growth capital from Avenue Capital. This strategic financing agreement will support the BLA filing of TA-ERT for the treatment of MPS IIIB, while also accelerating pre-launch commercial activities. https://t.co/f9T11s1dl0

[Spruce Biosciences @Spruce_Bio]

We welcome Keli Walbert to our Board of Directors. Keli brings decades of commercial leadership experience and a deep understanding of the rare disease landscape, which will be invaluable as we prepare for a transformative year ahead. https://t.co/0cK7PuE45d

[Spruce Biosciences @Spruce_Bio]

Today, we announced our third quarter 2025 financial results and corporate updates. Visit our ‘News & Events’ page to learn more about our latest company highlights including our recent financing and grant of Breakthrough Therapy Designation. https://t.co/RLhtuFnXf4 $SPRB

[Spruce Biosciences @Spruce_Bio]

The FDA has granted Breakthrough Therapy Designation for tralesinidase alfa enzyme replacement therapy (#TA-ERT) for the treatment of #MPSIIIB. Biologics License Application remains on track for Q1 2026. $SPRB https://t.co/KEEwIWpFRH

[Spruce Biosciences @Spruce_Bio]

We announced that the company has resumed trading on the Nasdaq Capital Market at the market open today, September 15, with the ticker symbol “SPRB” and CUSIP 85209E 208. Learn more in the press release: https://t.co/tv8ET4k6R9
$SPRB

[Spruce Biosciences @Spruce_Bio]

Today, we announced our second quarter 2025 financial results and corporate updates. Visit our ‘News & Events’ page to learn more about our latest company highlights and pipeline updates, and view the press release here: https://t.co/qCjg3MCPoo
$SPRB